Zacks Investment Research Lowers Alpine Immune Sciences (NASDAQ:ALPN) to Hold

Zacks Investment Research downgraded shares of Alpine Immune Sciences (NASDAQ:ALPN) from a buy rating to a hold rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

ALPN has been the subject of a number of other research reports. Oppenheimer set a $13.00 target price on Alpine Immune Sciences and gave the stock a buy rating in a research report on Tuesday, March 19th. ValuEngine lowered Zumiez from a hold rating to a sell rating in a research report on Tuesday, July 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $11.15.

Shares of NASDAQ:ALPN opened at $4.20 on Wednesday. Alpine Immune Sciences has a fifty-two week low of $3.66 and a fifty-two week high of $8.59. The stock has a 50-day simple moving average of $4.42. The company has a quick ratio of 7.33, a current ratio of 7.33 and a debt-to-equity ratio of 0.03.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.69) by ($0.01). Sell-side analysts forecast that Alpine Immune Sciences will post -2.67 earnings per share for the current year.

In other Alpine Immune Sciences news, VP James Paul Rickey bought 10,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was acquired at an average price of $4.95 per share, with a total value of $49,500.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 75.10% of the stock is currently owned by insiders.

An institutional investor recently bought a new position in Alpine Immune Sciences stock. Leonard Rickey Investment Advisors P.L.L.C. purchased a new stake in shares of Alpine Immune Sciences Inc (NASDAQ:ALPN) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $42,000. Leonard Rickey Investment Advisors P.L.L.C. owned about 0.05% of Alpine Immune Sciences as of its most recent SEC filing. Hedge funds and other institutional investors own 47.04% of the company’s stock.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.

Featured Article: What is intrinsic value?

Get a free copy of the Zacks research report on Alpine Immune Sciences (ALPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.